Exact Sciences price target raised to $54 from $52 at RBC Capital

RBC Capital raised the firm’s price target on Exact Sciences (EXAS) to $54 from $52 and keeps a Sector Perform rating on the shares after its Q1 results. The quarter has ushered the launch of Cologuard Plus and Oncodetect, keeping successful products center to the FY25 story, the analyst tells investors in a research note. The company’s pipeline updates like the BLUE-C readout in Summer of 2025 and second half’s CancerGuard launch provide key catalysts through the year, RBC adds.